Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This is a double-blind placebo-controlled clinical investigation into the efficacy and
tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension.
The primary outcome is the change in 6-minute walk distance from baseline to week 12.